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Cowden disease is an autosomal dominant syndrome
characterized by facial trichilemmomas, acral kera-
toses, papillomatous papules, mucosal lesions, and an
increased risk for breast and nonmedullary thyroid
cancer. Here, we describe a novel PTEN splicing site
mutation in a family with classical Cowden disease
and we studied benign skin lesions typical for
Cowden disease for loss of heterozygosity. We found
a PTEN IVS2 + 1G > A 5¢-splicing acceptor muta-
tion resulting in activation of a cryptic splice site.
Activation of this cryptic splice site is predicted to
result in a frameshift with a premature stop codon,
thus disrupting the phosphatase core motif of PTEN.
Loss of heterozygosity analysis of two trichilemmo-
mas, one ®broma, and three acanthomas of the
index patient demonstrated loss of heterozygosity at
the PTEN locus in four of these lesions. In conclu-
sion, our data demonstrate that a PTEN splicing site
mutation causes activation of a cryptic splice site,
which results in aberrant transcripts. Key words: genes,
suppressor, tumor/germline mutation/hamartoma syndrome,
multiple/keratosis/loss of heterozygosity/RNA splicing. J
Invest Dermatol 117:1650±1653, 2001
C
owden disease (CD) is an autosomal dominant
familial cancer syndrome characterized by the
development of hamartomas in multiple organs,
including skin, gastrointestinal tract, central nervous
system, breast, and thyroid. Diagnostic criteria have
been developed for the clinical identi®cation of CD: facial
trichilemmomas, acral keratoses, papillomatous papules, and
mucosal lesions are pathognomonic criteria for CD. Breast cancer,
nonmedullary thyroid cancer, macrocephaly, and dysplastic gang-
liocytoma of the cerebellum (Lhermitte±Duclos disease) are
considered as major criteria, whereas multinodular goiter, thyroid
adenoma, mental retardation, gastrointestinal hamartomatous
polyposis, ®brocystic breast disease, lipomas, ®bromas, and
genitourinary tumors or malformation are considered as minor
criteria (Nelen et al, 1996; Eng, 2000).
A gene responsible for CD was localized to chromosome 10q22±
23 (Nelen et al, 1999b) and germline mutations in this gene, named
PTEN (Li et al, 1997), MMAC1 (Steck et al, 1997), or TEP1 (Li
and Sun, 1997), were identi®ed in patients with CD (Liaw et al,
1997). PTEN encodes a ubiquitously expressed dual-speci®city
phosphatase and is mutated in a variety of sporadic malignancies (Li
et al, 1997; Steck et al, 1997). PTEN is important for the induction
of cell cycle arrest, apoptosis, but also affects cell adhesion,
migration, and differentiation, and thus is considered as a tumor
suppressor (Di Cristofano and Pandol®, 2000).
In this report, we describe a novel PTEN 5¢-splicing acceptor
site mutation in a family with classical CD. We show that this
mutation resulted in activation of cryptic splicing at the 3¢ site of
exon 2. These aberrant PTEN transcripts are predicted to be less
abundant than normally spliced PTEN transcripts. Furthermore,
loss of heterozygosity (LOH) at the PTEN gene locus in benign
skin lesions typical for CD was demonstrated.
MATERIALS AND METHODS
Case report A 73-y-old female patient (II.1) with a history of
multinodular goiter and ductal carcinoma in situ of the breast was
referred to our department for endoscopy because of familial intestinal
polyposis. Moderate macrocephaly, facial papules, small polypoid mucosal
lesions of the mouth, nasal papillomatous papules, and acral keratoses
were noted. Three further members of the patient's family were also
affected by mucocutaneous lesions and/or gastrointestinal polyposis
(Fig 1a). Endoscopy revealed multiple hyperplastic antral, duodenal, and
colorectal polyps with a maximum size of 5±10 mm. Because the
diagnosis of Cowden disease was suspected, mucocutaneous lesions were
biopsied and histologically classi®ed as facial trichilemmomas, ®bromas,
and mucocutaneous acanthomas. After genetic counseling and written
informed consent genetic testing for a PTEN germline mutation was
initiated.
DNA extraction and mutational analysis of PTEN Genomic DNA
was extracted from the index patient's peripheral blood mononuclear
cells using the QIAamp DNA mini kit (Qiagen, Hilden, Germany).
Polymerase chain reaction (PCR) ampli®cation of the coding region of
PTEN was carried out using published primer sets (Steck et al, 1997;
Marsh et al, 1998). Different primers were designed for exon 1 (forward,
5¢-CAGCTACCGCCAAGTCCAGAGCC-3¢), exon 3 (forward, 5¢-
TTTTTGTTAATGGTGGCTTTTTG-3¢), exon 6 (reverse, 5¢-
GATATGGTTAAGAAAACTGTTCC-3¢), exon 8 (reverse, 5¢-CAA-
GTCACCAACCCCCACAAAATG-3¢), and exon 9 (forward, 5¢-GAT-
GAGTCATATTTGTGGGTTTTC-3¢; reverse, 5¢-TCATGGTTGT-
TTTATCCCTCTTG-3¢). PCR products were directly sequenced
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(BigDye Ready Reaction Terminators; Applied Biosystems, Weiterstadt,
Germany).
Reverse transcription PCR (RT-PCR) and subcloning of PTEN
transcripts Total RNA was extracted from peripheral blood
mononuclear cells using TriStar reagent according to the manufacturer's
protocol (Sigma, Deisenhofen, Germany). Because of the presence of a
highly conserved PTEN pseudogene localized to chromosome 9p21
(Dahia et al, 1998; Whang et al, 1998), PTEN cDNA speci®c primers
(forward, 5¢-TTTCCATCCTGCAGAAGAAGC-3¢; reverse, 5¢-TAAA-
TATGCACATATCATTAC-3¢) spanning exons 1±5 were designed.
The pseudogene sequence showed a 4 bp deletion 65 bp upstream of the
translation start of PTEN (GenBank accession: AF343912), which was
used for the design of the forward primer. The reverse primer anneals to
a region in exon 5 that differs between PTEN mRNA and PTEN
pseudogene in three base pairs. PCR was carried out for 10 min at
95°C; followed by 45 cycles of 30 s at 95°C, 90 s at 55°C, and 2 min at
72°C; and 10 min at 72°C. RT-PCR products were cloned into
pCRTM2.1±TOPOTM (Invitrogen, Leek, The Netherlands), ampli®ed,
and directly sequenced.
LOH analysis of PTEN in benign skin lesions The PTEN gene
locus at chromosome 10q22±23 was studied for LOH by PCR
ampli®cation of the microsatellite markers D10S215, D10S249, and
D10S541 using published primer sequences (Gyapay et al, 1994). DNA
of paraf®n-embedded tissues was extracted after microdissection from
two trichilemmomas, one ®broma, and three acanthomas. PCR analysis
was performed as previously described (Trojan et al, 2000). To con®rm
LOH at the PTEN locus in mucocutaneous lesions heterozygosity at
PTEN exon 2 was analyzed by PCR ampli®cation and direct
sequencing.
RESULTS
Complete sequence analysis of PTEN of the index patient (II.1)
demonstrated a heterozygous G to A transversion at the 5¢-splice
acceptor site of exon 2 (IVS2 + 1G > A) (Fig 1b) with no further
mutation found in the entire coding sequence. This mutation was
absent in DNA from 20 unrelated healthy individuals. To test for
possible consequences of this splicing site mutation on PTEN pre-
mRNA splicing, RT-PCR was performed and PTEN transcripts
were sequenced. Sequencing of the PTEN pseudogene was
performed to design speci®c primers for PTEN transcripts. Direct
sequence analysis detected only PTEN wildtype sequence, sug-
gesting absence of aberrant transcripts. Because less abundant
aberrantly spliced PTEN transcripts could not constantly be
detected by dye-terminator sequencing techniques (Raizis et al,
2000), PCR products were cloned and sequenced. Two out of 10
clones carried a 5 bp deletion at the 3¢ site of PTEN exon 2
(Fig 2a), which is predicted to lead to a premature translational
stop at codon 60, whereas none of the 20 clones from healthy
probands carried this transcript. This internal deletion is anticipated
to result from the described 5¢-splice acceptor site mutation, which
activates a cryptic splice site resembling the 5¢-splicing site
consensus sequence (Maquat, 1996). An additional 50 clones
were PCR ampli®ed and analyzed for further aberrant transcripts
carrying larger deletions or insertions. Only one clone carried an
insert of larger size (Fig 2b). Sequence analysis revealed a complex
rearrangement with partial retention of PTEN intron 1 and
skipping of exon 2 (Fig 2c).
DNA extracted from microdissected tissue sections histologically
characterized as perifollicular ®broma and acanthomas, respectively,
demonstrated LOH at the microsatellite marker D10S541, which is
located distal to the PTEN locus. Two other acanthomas
demonstrated LOH at the intragenic PTEN microsatellite marker
Figure 1. Mutation analysis of PTEN. (a) Pedigree of a family with
classical Cowden disease. Phenotypically affected family members are
denoted by ®lled symbols. Numbers indicate the age of diagnosis with a
malignant tumor. Underlined, index patient; BT, brain tumor; DCIS,
ductal carcinoma in situ of the breast; STS, soft-tissue sarcoma; *, blood
available for PTEN mutation analysis. (b) A heterozygous PTEN
germline mutation of the 5¢-splice acceptor site of exon 2
(IVS2 + 1G > A) was identi®ed in the index patient (II.1), whereas a
phenotypically unaffected grandson (IV.1) carried only the wildtype
sequence (arrowheads).
Figure 2. RT-PCR ampli®cation and subcloning of PTEN
transcripts from a patient with Cowden disease. (a) PTEN wildtype
transcript sequence was found in eight of 10 clones (upper panel), but two
clones carried a 5 bp deletion at the 3¢ site of PTEN exon 2 (lower
panel), which is predicted to result in a truncated protein. (b) Size
differences between wildtype (lanes 1±6, 10, and 11) and cryptic spliced
PTEN transcripts (lanes 8# and 9#) were not detected. One (lane 7*) out
of 60 clones carried an insert of larger size. (c) Sequence analysis of this
clone showed a complex rearrangement with partial retention of PTEN
intron 1 and skipping of exon 2. The retained intronic sequence
contained a 76 bp sequence of the 5¢ site of intron 1 followed by 81 bp
of a further downstream ``exon-like'' sequence of intron 1.
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D10S249 (Fig 3a). Sequence analysis demonstrated hemizygosity
for the wildtype allele at PTEN IVS2 + 1 in the two acanthomas
with LOH at D10S249, indicating complete loss of the mutant
allele (Fig 3b). The remaining ®ve mucocutaneous lesions were
heterozygous at PTEN IVS2 + 1 (data not shown).
DISCUSSION
In this study, we describe a novel PTEN splicing site mutation in a
family with classical CD. Ten different PTEN splicing site
mutations in patients with CD have been reported (Bonneau and
Longy, 2000; Celebi et al, 2000). The described PTEN
IVS2 + 1G > A splicing acceptor site mutation resulted in
activation of a cryptic splice site and a complex rearrangement of
PTEN with a partial retention of PTEN intron 1 and skipping of
exon 2. This ®nding, which has not yet been described in patients
with CD, is in accordance with current knowledge of splicing site
defects of other genes, causing either exon skipping, activation of a
cryptic splice site, intron retention as part of the mRNA, or a
combination of these events (Maquat, 1996). Although splicing
variants of PTEN have been described in healthy subjects (Sharrard
and Maitland, 2000), the reported aberrantly spliced transcripts
were exclusively detected in the patient with CD.
Our initial strategy to directly detect mutant PTEN transcripts
failed, indicating that the mutated PTEN mRNA is not stable or
cannot be detected using dye-based sequencing techniques in the
presence of wildtype transcripts (Raizis et al, 2000). After
subcloning of the RT-PCR products aberrant PTEN transcripts
resulting from activation of a cryptic splice site were detected. The
aberrantly spliced transcripts are predicted to result in a frameshift
with a premature stop codon, which will probably lead to
nonsense-mediated decay of the mRNA (Maquat, 1996). Because
the phosphatase core motif encoded by exon 5 is disrupted by the
resulting premature termination codon, we speculate that the
PTEN phosphatase activity is abolished.
It has been established that PTEN acts as a tumor suppressor in
different malignant tumors (Di Cristofano and Pandol®, 2000).
Nevertheless, the role of PTEN in the development of benign,
CD-associated epidermal lesions without potential to progress
toward a malignant tumor was not previously investigated. In this
study, we detected LOH at the PTEN locus in some acanthomas
and in a perifollicular ®broma. This ®nding is in accordance with
other studies, reporting LOH in ®broadenomas of the breast,
hamartomas of the lung and stomach, juvenile colonic polyps, and
colonic adenomas of patients with CD (Lynch et al, 1997; Chi et al,
1998; Marsh et al, 1998a). We observed that LOH at the PTEN
locus was also associated with loss of the mutant allele in two
hyperplastic skin lesions, however, which seems to be in contra-
diction with current ideas on tumor development in cases of PTEN
haplo-insuf®ciency. Although it cannot be excluded that this
®nding is coincidental or arti®cial because of the tissue ®xation
process, others have also reported loss of the mutant PTEN allele
from apparently normal tissue adjacent to a ductal carcinoma in situ
of the breast and a thyroid adenoma in patients with CD harboring
a PTEN germline mutation (Lynch et al, 1997). Studies with
Pten+/± mice suggest that in Pten haplo-insuf®ciency Fas-dependent
apoptosis is impaired, which increases survival and proliferation of
certain cell types leading to a hyperplastic-dysplastic phenotype (Di
Cristofano et al, 1999). In the case of accumulation of DNA
damage, including LOH at the Pten locus, neoplastic transformation
in mice might ultimately arise from total PTEN loss (Di Cristofano
and Pandol®, 2000). Our ®nding that hyperplastic epidermal lesions
in a patient with CD are associated with LOH at the PTEN locus,
partially involving the mutant allele, further supports the role of
PTEN insuf®ciency for increased proliferation of epidermal cells. It
remains to be established why PTEN loss in these epidermal lesions
is not associated with neoplastic transformation, however.
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